Business
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
TORONTO and HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced the appointment of Dr. Nageatte Ibrahim, MD, as Chief Medical Officer. Dr. Ibrahim will serve in a fractional capacity, bringing extensive clinical development and oncology expertise to support the advancement of the Co
About this update from Merck & Company, Inc.
[{"type":"image","alt":"Medicenna Therapeutics Corp.","displaySize":"","headline":null,"caption":"Medicenna Therapeutics Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/33fcbf6dc1c4c8dceac4cdb8f9da49c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ra8Fx_87O2AATpVkKsGYOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUz/https://media.zenfs.com/en/globenewswire.com/33fcbf6dc1c4c8dceac4cdb8f9da49c2","width":300,"height":38}},"lazy":false},{"type":"text","content":"TORONTO and HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced the appointment of Dr. Nageatte Ibrahim, MD, as Chief Medical Officer. Dr. Ibrahim will serve in a fractional capacity, bringing extensive clinical development and oncology expertise to support the advancement of the Company’s pipeline.","length":527,"tagName":"p"},{"type":"text","content":"Dr. Ibrahim, former Chief Medical Officer of Oncology at Innovent Biologics USA, brings more than two decades of experience spanning oncology drug development, including over 12 years at Merck and GSK, and 9 years in academia where she held faculty and clinical appointments at Harvard Medical School, Dana-Farber Cancer Institute, and the Perelman School of Medicine at the University of Pennsylvania.","length":402,"tagName":"p"},{"type":"text","content":"“We are thrilled to welcome Dr. Ibrahim to Medicenna at this pivotal stage of our clinical development,” said Dr. Fahar Merchant, President and Chief Executive Officer of Medicenna. “Her deep expertise in global oncology drug development, including leadership on multiple landmark immunotherapy programs, will be instrumental as we advance our IL-2 superagonist platform and expand our clinical pipeline with our first-in-class antiPD1-IL-2 bifunctional program. Trained as a physician and scientist, she played a pivotal role in the development of the world’s best selling oncology drug, pembrolizumab, an anti-PD1 immunotherapy that has changed the treatment landscape for many cancers. Nageatte is a natural fit for Medicenna’s superkine immunotherapy pipeline, especially development of anti...